{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:34:39Z","timestamp":1778589279474,"version":"3.51.4"},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,1,10]],"date-time":"2011-01-10T00:00:00Z","timestamp":1294617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold><jats:styled-content>Purpose:<\/jats:styled-content>\u2002<\/jats:bold> Verapamil add\u2010on treatment has been suggested as a novel therapeutic concept for overcoming transporter\u2010mediated pharmacoresistance. Efficacy data have been limited so far to case reports in individual epileptic patients. Therefore, we aimed to thoroughly evaluate the efficacy and tolerability of verapamil add\u2010on treatment.<\/jats:p><jats:p><jats:bold><jats:styled-content>Methods:<\/jats:styled-content>\u2002<\/jats:bold> In a prestudy in healthy Beagle dogs the tolerability of verapamil add\u2010on treatment was investigated. The efficacy of verapamil was then evaluated in 11 dogs with phenobarbital\u2010resistant epilepsy.<\/jats:p><jats:p><jats:bold><jats:styled-content>Key Findings:<\/jats:styled-content>\u2002<\/jats:bold> Verapamil add\u2010on treatment (6.2\u20137.3\u2003mg\/kg) did not affect phenobarbital concentrations in plasma or cerebrospinal fluid. Side effects observed in healthy as well as in epileptic dogs comprised bradycardia and a decrease in blood pressure. Therefore, we had to limit the dosage to 1\u20131.5\u2003mg\/kg in the main study. In phenobarbital nonresponders, verapamil failed to improve seizure control. Verapamil treatment was discontinued prematurely in five animals due to worsening of seizure control or lack of an effect. In the remaining animals, seizure frequency tended to increase during the verapamil add\u2010on phase, reaching a mean of two seizures per month compared to the pre\u2010verapamil phase with phenobarbital monotherapy (mean of 1.4 seizures per month). In view of the detrimental effects in the majority of the dogs, the study had to be discontinued and no further animals were enrolled.<\/jats:p><jats:p><jats:bold><jats:styled-content>Significance:<\/jats:styled-content>\u2002<\/jats:bold> The failure of the maximum tolerated dosage to improve seizure control in dogs with phenobarbital\u2010resistant epilepsy argues against the suitability of verapamil add\u2010on treatment to overcome pharmacoresistance. Deterioration of seizure control in some individual animals suggests that verapamil might also exert unfavorable effects on seizure thresholds or its spread.<\/jats:p>","DOI":"10.1111\/j.1528-1167.2010.02886.x","type":"journal-article","created":{"date-parts":[[2011,1,10]],"date-time":"2011-01-10T17:20:20Z","timestamp":1294680020000},"page":"284-291","source":"Crossref","is-referenced-by-count":27,"title":["Add\u2010on treatment with verapamil in pharmacoresistant canine epilepsy"],"prefix":"10.1111","volume":"52","author":[{"given":"Melanie","family":"Jambroszyk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Tipold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidrun","family":"Potschka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,1,10]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.5.740"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.107.041210"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2006.06.014"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.7.4.447"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.59204.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2009.02.014"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(97)00035-X"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1728"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.21204.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)91099-8"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1556\/AVet.56.2008.4.5"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.152520"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2008.10.010"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-5616(96)50105-1"},{"key":"e_1_2_6_16_1","first-page":"97","article-title":"Oncology of companion animals as a model for humans. an overview of tumor histotypes","volume":"25","author":"Porrello A","year":"2006","journal-title":"J Exp Clin Cancer Res"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(02)00423-8"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.22-14-05833.2002"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00765.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E068"},{"key":"e_1_2_6_21_1","first-page":"186","article-title":"Idiopathic epilepsy in dogs","volume":"20","author":"Thomas W","year":"2000","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cvsm.2009.09.004"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327480301000207"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00496.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.121178"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj2810577"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2009.01.009"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2010.02886.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2010.02886.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T16:43:12Z","timestamp":1697388192000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2010.02886.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,10]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1111\/j.1528-1167.2010.02886.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2010.02886.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,10]]}}}